Atea Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 75
- Market Cap
- $324.1M
- Website
- http://www.ateapharma.com
Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir
Phase 1
Completed
- Conditions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT06356194
- Locations
- 🇨🇦
Atea Study Site, Québec, Montreal, Canada
Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06204679
- Locations
- 🇺🇸
Atea Study Site, Cypress, California, United States
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 275
- Registration Number
- NCT05904470
- Locations
- 🇹🇷
Atea Study Site, Kayseri, Turkey
The Study of Bemnifosbuvir in Healthy Japanese Subjects
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT05905497
- Locations
- 🇺🇸
Atea Study Site, Cypress, California, United States
Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT05905484
- Locations
- 🇨🇦
Atea Study Site, Québec, Montreal, Quebec, Canada
Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05731843
- Locations
- 🇨🇦
Atea Study Site, Québec, Montreal, Quebec, Canada
Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT05724693
- Locations
- 🇺🇸
Atea Study Site Orlando Clinical Research Center, Orlando, Florida, United States
SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 2295
- Registration Number
- NCT05629962
- Locations
- 🇲🇽
Atea Study site, San Luis Potosí, San Luis Potos, Mexico
🇹🇷Atea Study SIte, Kayseri, Turkey
🇬🇧Atea Study Site, Castleford, West Yourkshire, United Kingdom
Study of AT-527 in Subjects With Normal and Impaired Renal Function
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05618314
- Locations
- 🇨🇦
Atea Study Site, Québec, Canada
Study of AT-752 in Patients With Dengue Infection
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT05466240
- Locations
- 🇻🇳
Atea Study Site, Hanoi, Vietnam
© Copyright 2024. All Rights Reserved by MedPath